Literature DB >> 913018

Nifedipine, a new antihypertensive with rapid action.

M Guazzi, M T Olivari, A Polese, C Fiorentini, F Magrini, P Moruzzi.   

Abstract

Oral (17 cases) or sublingual (9 cases) administration of nifedipine (10 mg), a new coronary dilator, induced a prompt and large pressure reduction in patients with severe primary hypertension. Pressure started to fall within 20 and 5 min after oral and sublingual administration, respectively, and reached the lowest levels in the next 10 min. Maximal mean arterial pressure reduction averaged 36 mm Hg; 120 min after the drug, mean arterial pressure was diminished by 19.5% of control. The hypotension was mediated through diminished peripheral resistance associated with rise of cardiac output and pulse rate. Nifedipine was also administered siblingually in 3 cases with hypertensive encephalopathy and acute left ventricular failure with average systemic and pulmonary arterial pressures from 307/164 and 91/55 mm Hg, respectively, which fell to 237/115 and 68/35 mm Hg 15 min after 10 mg of the drug, and were further reduced to 176/89 and to 47/19 mm Hg by an additional 10 mg.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 913018     DOI: 10.1002/cpt1977225part1528

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

1.  Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.

Authors:  A Ferro; M Salvatore; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

2.  Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring.

Authors:  H Kambara; I H Mohiuddin; N Tamaki; T Fudo; M Hayashi; R Nohara; J Konishi; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

5.  Nifedipine attenuates the hypertensive response to tracheal intubation in pregnancy-induced hypertension.

Authors:  N Kumar; Y K Batra; I Bala; S Gopalan
Journal:  Can J Anaesth       Date:  1993-04       Impact factor: 5.063

6.  Diltiazem and verapamil: functional antagonism of exogenous noradrenaline and angiotensin II in man.

Authors:  D Magometschnigg; H Hörtnagl; H Rameis
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Verapamil in primary pulmonary hypertension.

Authors:  I Malcić; D Richter
Journal:  Br Heart J       Date:  1985-03

9.  Nifedipine attenuates the intraocular pressure response to intubation following succinylcholine.

Authors:  B Indu; Y K Batra; G D Puri; H Singh
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

10.  Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls--a proximal tubular effect?

Authors:  L R Krusell; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.